The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 41 | — | 20.1x | Near average | |
Growth | 6 | -81.8% | 5.6% | Below average | |
Quality | 96 | 130.6% | 7.6% | Above average | |
Safety | 31 | 0.1x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
BioAtla, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy BioAtla, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
BioAtla stock shows a state of complete stability in analyst estimates over recent periods (1, 7, and 30 days), with the target price stabilizing at 250 dollars. However, it should be noted that this consensus results from the coverage of only one analyst, which eliminates any dispersion in opinions but simultaneously increases concentration risk and reduces the comprehensiveness of the analytical view of the stock.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.